HK1115598A1 - Humanised antibodies specific for nogo-a and pharmaceutical uses thereof - Google Patents
Humanised antibodies specific for nogo-a and pharmaceutical uses thereofInfo
- Publication number
- HK1115598A1 HK1115598A1 HK08105409.6A HK08105409A HK1115598A1 HK 1115598 A1 HK1115598 A1 HK 1115598A1 HK 08105409 A HK08105409 A HK 08105409A HK 1115598 A1 HK1115598 A1 HK 1115598A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- nogo
- antibodies specific
- pharmaceutical uses
- humanised antibodies
- humanised
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0513766A GB0513766D0 (en) | 2005-07-05 | 2005-07-05 | Immunoglobulins |
GB0525448A GB0525448D0 (en) | 2005-12-14 | 2005-12-14 | Immunoglobulins |
PCT/EP2006/006535 WO2007003421A2 (fr) | 2005-07-05 | 2006-07-03 | Immunoglobulines |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1115598A1 true HK1115598A1 (en) | 2008-12-05 |
Family
ID=37604821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK08105409.6A HK1115598A1 (en) | 2005-07-05 | 2008-05-15 | Humanised antibodies specific for nogo-a and pharmaceutical uses thereof |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1899377B1 (fr) |
JP (1) | JP2009500363A (fr) |
KR (1) | KR20080030960A (fr) |
AU (1) | AU2006265276B2 (fr) |
BR (1) | BRPI0612734A2 (fr) |
CA (1) | CA2614076A1 (fr) |
CR (1) | CR9623A (fr) |
CY (1) | CY1113310T1 (fr) |
DK (1) | DK1899377T3 (fr) |
EA (1) | EA014291B1 (fr) |
ES (1) | ES2391902T3 (fr) |
HK (1) | HK1115598A1 (fr) |
HR (1) | HRP20120851T1 (fr) |
IL (1) | IL188282A (fr) |
MA (1) | MA29625B1 (fr) |
NO (1) | NO20076663L (fr) |
NZ (1) | NZ564567A (fr) |
PL (1) | PL1899377T3 (fr) |
PT (1) | PT1899377E (fr) |
SG (1) | SG162829A1 (fr) |
SI (1) | SI1899377T1 (fr) |
WO (1) | WO2007003421A2 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006114115A1 (fr) | 2005-04-26 | 2006-11-02 | Trion Pharma Gmbh | Combinaison d'anticorps et de glucocorticoides destinee au traitement du cancer |
CN102838673B (zh) | 2007-06-25 | 2016-05-11 | 艾斯巴技术-诺华有限责任公司 | 修饰抗体的方法和具有改善的功能性质的修饰抗体 |
DK2207808T3 (da) * | 2007-11-02 | 2013-08-05 | Novartis Ag | Forbedrede Nogo-A-bindingsmolekyler samt deres farmaceutiske anvendelse |
JP2011527317A (ja) * | 2008-07-11 | 2011-10-27 | グラクソ グループ リミテッド | Nogo−aアンタゴニストによる筋萎縮性側索硬化症の治療 |
GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
BR112021012065A2 (pt) | 2018-12-21 | 2021-12-07 | Kymab Ltd | Anticorpo biespecífico que se liga a fixa e fx e catalisa a ativação de fx mediada por fixa; método; anticorpo anti-fixa; anticorpo anti-fx; ácido nucleico isolado; célula hospedeira in vitro; população de células hospedeiras in vitro; kit para produção de um anticorpo biespecífico; método de produção de um anticorpo biespecífico; composição; método para controlar o sangramento em um paciente com hemofilia a; uso de um anticorpo biespecífico; método, composição para uso ou uso; e método para reduzir o desenvolvimento de anticorpos antifármacos inibidores em um paciente com hemofilia a em tratamento com um polipeptídeo que substitui a atividade de fviiia |
GB2590642B (en) * | 2019-12-20 | 2024-02-14 | Kymab Ltd | Improved lambda antibodies |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0228832D0 (en) * | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
GB0321997D0 (en) * | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
AU2004303585B2 (en) * | 2003-12-22 | 2010-12-23 | Glaxo Group Limited | NOGO-a neutralising immunoglobulins for treatment of neurological diseases |
-
2006
- 2006-07-03 WO PCT/EP2006/006535 patent/WO2007003421A2/fr active Application Filing
- 2006-07-03 NZ NZ564567A patent/NZ564567A/en not_active IP Right Cessation
- 2006-07-03 CA CA002614076A patent/CA2614076A1/fr not_active Abandoned
- 2006-07-03 JP JP2008519855A patent/JP2009500363A/ja not_active Ceased
- 2006-07-03 SG SG201004551-6A patent/SG162829A1/en unknown
- 2006-07-03 EP EP06776123A patent/EP1899377B1/fr active Active
- 2006-07-03 EA EA200702634A patent/EA014291B1/ru not_active IP Right Cessation
- 2006-07-03 ES ES06776123T patent/ES2391902T3/es active Active
- 2006-07-03 DK DK06776123.9T patent/DK1899377T3/da active
- 2006-07-03 SI SI200631454T patent/SI1899377T1/sl unknown
- 2006-07-03 AU AU2006265276A patent/AU2006265276B2/en not_active Ceased
- 2006-07-03 PL PL06776123T patent/PL1899377T3/pl unknown
- 2006-07-03 PT PT06776123T patent/PT1899377E/pt unknown
- 2006-07-03 BR BRPI0612734-7A patent/BRPI0612734A2/pt not_active IP Right Cessation
- 2006-07-03 KR KR1020077031031A patent/KR20080030960A/ko not_active Application Discontinuation
-
2007
- 2007-12-20 CR CR9623A patent/CR9623A/es not_active Application Discontinuation
- 2007-12-20 IL IL188282A patent/IL188282A/en not_active IP Right Cessation
- 2007-12-28 NO NO20076663A patent/NO20076663L/no not_active Application Discontinuation
-
2008
- 2008-01-09 MA MA30565A patent/MA29625B1/fr unknown
- 2008-05-15 HK HK08105409.6A patent/HK1115598A1/xx not_active IP Right Cessation
-
2012
- 2012-10-23 HR HRP20120851TT patent/HRP20120851T1/hr unknown
- 2012-11-05 CY CY20121101051T patent/CY1113310T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EA200702634A1 (ru) | 2008-06-30 |
EA014291B1 (ru) | 2010-10-29 |
EP1899377B1 (fr) | 2012-08-22 |
AU2006265276A1 (en) | 2007-01-11 |
PT1899377E (pt) | 2012-11-20 |
CY1113310T1 (el) | 2016-04-13 |
KR20080030960A (ko) | 2008-04-07 |
PL1899377T3 (pl) | 2013-01-31 |
SG162829A1 (en) | 2010-07-29 |
SI1899377T1 (sl) | 2012-12-31 |
IL188282A0 (en) | 2008-04-13 |
WO2007003421A2 (fr) | 2007-01-11 |
HRP20120851T1 (hr) | 2012-11-30 |
CA2614076A1 (fr) | 2007-01-11 |
NZ564567A (en) | 2010-09-30 |
ES2391902T3 (es) | 2012-11-30 |
JP2009500363A (ja) | 2009-01-08 |
MA29625B1 (fr) | 2008-07-01 |
AU2006265276B2 (en) | 2011-10-13 |
WO2007003421A3 (fr) | 2007-04-12 |
EP1899377A2 (fr) | 2008-03-19 |
NO20076663L (no) | 2008-02-27 |
CR9623A (es) | 2008-04-10 |
IL188282A (en) | 2011-04-28 |
DK1899377T3 (da) | 2012-11-12 |
BRPI0612734A2 (pt) | 2010-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL272883A (en) | Monoclonal antibodies and their uses | |
IL187710A0 (en) | Anti-trkb monoclonal antibodies and uses thereof | |
IL240245A (en) | 5t4 antibodies and their uses | |
HK1208228A1 (en) | Antibodies and immunoconjugates and uses therefor | |
EP1940466A4 (fr) | Anticorps monoclonal anti-addl et leur utilisation | |
IL194995A0 (en) | Modified humanised anti-interleukin-18 antibodies | |
IL206709A0 (en) | Il-31 monoclonal antibodies | |
IL222922A (en) | Antibodies against neurophilin-1 and their use | |
SG10201404801YA (en) | Monoclonal antibody | |
IL196550A0 (en) | Anti-il-6 monoclonal antibodies and uses thereof | |
HK1182721A1 (zh) | 抗體和免疫偶聯物及其用途 | |
AP2008004471A0 (en) | Anti-Alpha2 Intergin antibodies and their uses | |
IL200610A0 (en) | Human monoclonal anti-ip-10 antibodies and uses thereof | |
IL184024A0 (en) | Irta-5 antibodies and their uses | |
HK1111177A1 (en) | M-csf specific monoclonal antibody and uses thereof m-csf | |
IL220622A0 (en) | Monoclonal antibodies against activated and unactivated protein c | |
ZA201001260B (en) | Immunogenic polypeptides and monoclonal antibodies | |
HK1115598A1 (en) | Humanised antibodies specific for nogo-a and pharmaceutical uses thereof | |
EP2077325A4 (fr) | Anticorps monoclonal et son utilisation | |
ZA200800047B (en) | Humanised antibodies specific for NOGO-A and pharmaceutical uses thereof | |
EP1944323A4 (fr) | Nouvel anticorps monoclonal et utilisation de celui-ci | |
ZA200705716B (en) | IRTA-2 antibodies and their uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20160703 |